Search

Résumé: La diffusion de données et d'indicateurs à l'équipe de la pharmacie comporte plusieurs bénéfices théoriques, mais ceux-ci sont peu diffusés et doivent être adaptés aux besoins de l'équipe. Méthodes. Étude descriptive transversale. L'objectif est de décrire l'utilisation actuelle et projetée d'indicateurs de gestion en pharmacie hospitalière au sein d'un centre hospitalier universitaire. La situation actuelle de la diffusion et de l'utilisation de données et d'indicateurs a été décrite. Des indicateurs et données d'intérêt ont été identifiés par revue de la littérature et en consultant les chefs d'équipe des secteurs visés. Un sondage a été envoyé à l'équipe. Chaque répondant devait coter les indicateurs d'intérêt de leur(s) secteur(s) de pratique selon un score de priorité d'affichage, permettant de calculer un score pondéré pour chaque donnée et indicateur. Résultats. Cinquante-sept réponses ont été obtenues (taux de participation de 63,3 % ; 57/90 personnes disponibles, soit 31 pharmaciens, 23 préparateurs, 2 membres non identifiés et 1 membre autre). Des 93 données et indicateurs proposés, le score pondéré de priorité d'affichage varie de 1,44 à 4,05 par item (moyenne de 2,69 ± 0,52). En utilisant arbitrairement un seuil de 2,5 ou moins, 37 de ces données et indicateurs ont été priorisés. Conclusion. Cette étude décrit une démarche structurée pour évaluer et sélectionner des données et indicateurs en vue de les diffuser aux membres d'un département de pharmacie via un tableau de bord. Un total de 93 données et indicateurs ont été identifiés par les membres de l'équipe afin de soutenir les pratiques en pharmacie hospitalière. Several theoretical benefits of disseminating data and indicators to the pharmacy team exist, but they are not usually distributed, and they must be adapted to the pharmacy team's needs. Methods: This is a descriptive cross-sectional study. The objective is to describe the current and projected use of hospital pharmacy management indicators within a university hospital center. The current state of dissemination and use of data and indicators was described. Indicators and data of interest were identified from a literature review and by consulting targeted sectors' team leaders. A survey was sent to the team where each respondent rated the indicators of interest for their area(s) of practice according to a display priority score, allowing for a weighted score to be calculated for each data and indicator. Results: Fifty-seven responses were obtained (participation rate of 63.3%; 57/90 people available, i.e., 31 pharmacists, 23 preparers, 2 unidentified members and 1 other member). Of the 93 data and indicators available, the weighted display priority score ranges from 1.44 to 4.05 per item (average of 2.69 ± 0.52). Using an arbitrary threshold of 2.5 or less, 37 of these data and indicators were prioritized. Conclusion: This study describes a structured process for evaluating and selecting data and indicators with the objective to share them to members of a pharmacy department via a dashboard. A total of 93 data and indicators were identified by team members to support hospital pharmacy practices. [ABSTRACT FROM AUTHOR]

Background: Deprescribing, a relatively recent concept, has been proposed as a promising solution to the growing issues of polypharmacy and use of medications of questionable benefit among older adults. However, little is known about the health outcomes of deprescribing interventions. Objective: This paper presents the protocol of a study that aims to contribute to the knowledge on deprescribing by addressing two specific objectives: (1) describe the impact of deprescribing in adults ≥60 years on health outcomes or quality of life; and (2) determine the characteristics of effective interventions in deprescribing. Methods: Primary studies targeting three concepts (older adults, deprescribing, and health or quality of life outcomes) will be included in the review. The search will be performed using key international databases (MEDLINE, EMBASE, CINAHL, Ageline, PsycInfo), and a special effort will be made to identify gray literature. Two reviewers will independently screen the articles, extract the information, and evaluate the quality of the selected studies. If methodologically feasible, meta-analyses will be performed for groups of intervention studies reporting on deprescribing interventions for similar medications, used for similar or identical indications, and reporting on similar outcomes (eg, benzodiazepines used against insomnia and studies reporting on quality of sleep or quality of life). Alternatively, the results will be presented in bottom-line statements (objective 1) and a matrix outlining effective interventions (objective 2). Results: The knowledge synthesis may be limited by the availability of high-quality clinical trials on deprescribing and their outcomes in older adults. Additionally, analyses will likely be affected by studies on the deprescribing of different types of molecules within the same indication (eg, different pharmacological classes and medications to treat hypertension) and different measures of health and quality of life outcomes for the same indication. Nevertheless, we expect the review to identify which deprescribing interventions lead to improved health outcomes among seniors and which of their characteristics contribute to these outcomes. Conclusions: This systematic review will contribute to a better understanding of the health outcomes of deprescribing interventions among seniors. [ABSTRACT FROM AUTHOR]

Mixed phenotype acute leukemia (MPAL) is a rare type of acute leukemia where blasts present phenotypes from more than one lineage. A poor prognostic has been associated with this disease, and limited data are currently available to guide the choice of therapy. Regarding FLT3‐positive MPAL, only one case treated with midostaurin has been published to date. Here, we report the successful use of midostaurin to treat three FLT3‐positive MPAL T/myeloid and B/myeloid patients. Midostaurin was successfully added to intensive induction (two patients) and consolidation chemotherapy (three patients) without significant adverse events requiring a dose adjustment or discontinuation. The therapy received resulted in complete remission for two patients and complete remission with an incomplete hematologic recovery for the third. All patients proceeded to HSCT and stayed in remission after an extended follow‐up respectively at 28, 31, and 11 months later. These results suggest that the addition of midostaurin during induction and consolidation therapy may represent a treatment option for FLT3‐positive MPAL. [ABSTRACT FROM AUTHOR]